

August 9, 2018

To Listing Department, NATIONAL STOCK EXCHANGE OF INDIA LIMITED Exchange Plaza, Bandra Kurla Complex, Bandra (E), MUMBAI -400 051 Company Code No. AUROPHARMA	To The Corporate Relations Department BSE LIMITED Phiroz Jeejeebhoy Towers, 25 th floor, Dalal Street, MUMBAI -400 001 Company Code No. 524804
--	--

Dear Sir,

Sub: Un-audited Financial Results for the first Quarter ended 30th June, 2018.

Pursuant to Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we enclose herewith the Un-audited Financial Results of the Company for the first Quarter ended 30th June, 2018, as were approved at the Meeting of the Board of Directors of the Company held on 9th August, 2018 along with Limited Review Reports of the Statutory Auditors of the Company.

The Board meeting commenced at 2.00 p.m and concluded at 5.00 p.m.

Please take the information on record.

Thanking you,

Yours faithfully,
For AUROBINDO PHARMA LIMITED


B. Adi Reddy
Company Secretary



AUROBINDO PHARMA LIMITED

(CIN - L24239TG1986PLC015190)

Regd. Office: Plot No.2, Maitrivihar, Ameerpet, Hyderabad - 500 038, India
Tel: +91 040 23736370 ; Fax: +91 40 23747340 ; Email: info@aurobindo.com

(Rs. In lakhs)

STATEMENT OF STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30.06.2018

Particulars	Quarter ended				Year ended	
	30.06.2018	31.03.2018	30.06.2017	31.03.2018	30.06.2017	31.03.2018
	Unaudited	Audited	Unaudited	Audited	Unaudited	Audited
1 Revenue from operations						
(a) Net sales/ income from operations (refer note 3)	249,162	229,632	213,178	1,004,196		
(b) Other operating income	6,720	5,840	5,651	26,119		
Total revenue from operations	255,882	235,472	218,829	1,030,315		
2 Other income						
(a) Foreign exchange gain (net)	-	295	616	5,853		
(b) Others	282	341	551	2,212		
Total other income	282	636	1,167	8,065		
Total Income (1+2)	256,164	236,108	219,996	1,038,380		
3 Expenses						
(a) Cost of materials consumed	143,397	119,149	119,790	489,327		
(b) Purchases of stock-in-trade	253	42	110	372		
(c) Changes in inventories of finished goods, stock-in-trade and work-in-progress	(11,913)	(9,049)	(21,597)	(33,418)		
(d) Employee benefits expense	31,929	31,739	25,976	113,164		
(e) Finance costs	2,387	1,741	1,025	5,289		
(f) Foreign exchange loss (net) (refer note 8)	4,996	-	-	-		
(g) Depreciation expense	9,366	9,155	8,339	35,483		
(h) Other expenses	47,544	45,803	45,691	193,869		
Total expenses	227,959	198,580	179,334	804,086		
4 Profit before tax (1+2-3)	28,205	37,528	40,662	234,294		
5 Tax expense	5,693	6,699	9,929	53,017		
6 Net profit for the period (4-5)	22,512	30,829	30,733	181,277		
7 Other Comprehensive (expense) / income - items that will not be reclassified to profit or loss (net of tax)	(63)	193	(154)	(218)		
8 Total Comprehensive income for the period (6+7)	22,449	31,022	30,579	181,059		
9 Paid-up equity share capital (face value Re. 1 per share)	5,859	5,859	5,859	5,859		
10 Other equity						
11 Earnings per equity share of Re. 1 each (not annualised)						
(a) Basic (in Rs.)	3.84	5.26	5.25	30.94		
(b) Diluted (in Rs.)	3.84	5.26	5.25	30.94		

NOTES:

- The financial results of the Company have been prepared in accordance with the Indian Accounting Standards (Ind AS) prescribed under Section 133 of the Companies Act, 2013, read with the relevant rules issued thereunder.
- The above standalone financial results as reviewed by the audit committee have been approved by the Board of Directors at its meeting held on 09 August 2018.
- Post implementation of Goods and Services Tax ('GST') with effect from 01 July 2017, revenues from operations is disclosed net of GST. Revenue from operations for the quarter ended 30 June 2018 and 31 March 2018 are reported net of GST. Revenue from operations for the quarter ended 30 June 2017 includes excise duty which is now subsumed in GST. The year ended 31 March 2018 includes excise duty upto 30 June 2017.
- Effective 01 April 2018, the Company has adopted Ind AS 115 "Revenue from Contracts with Customers". The adoption of the standard did not have material impact on the financial results of the Company.
- The Company operates in only one segment viz., 'Pharmaceutical Products'.
- During the quarter, Aurobindo Pharma USA LLC which was dissolved on 31 March 2018 was revived on 06 June 2018.
- Sales of standalone for current quarter include exports of Rs.204,841 lakhs (30 June 2017: Rs. 178,908 lakhs).
- Foreign exchange loss includes exchange difference arising from foreign currency borrowings to the extent that they are regarded as an adjustment to finance cost as per para 6(e) of "Ind AS 23" on Borrowing costs.
- The figures for the quarter ended 31 March 2018 are the balancing figures between audited figures in respect of the full financial year upto 31 March 2018 and the unaudited published year to date figures upto 31 December 2017, which were subjected to the limited review only by the statutory auditors.
- Previous period figures have been regrouped/rearranged wherever considered necessary to conform to the current period presentation.

Place: Hyderabad
Date : 09 August 2018



www.aurobindo.com

By Order of the Board

N. Govindarajan
Managing Director



FOR IDENTIFICATION ONLY

B S R & Associates LLP

Chartered Accountants

Salarpuria Knowledge City
Orwell, 6th Floor, Unit-3
Sy. No. 83/1, Plot No. 2, Raidurg
Hyderabad-500081, India

Telephone : +91 40 7182 2000
Fax : +91 40 7182 2399

Limited Review Report on quarterly unaudited standalone financial results of Aurobindo Pharma Limited pursuant to Regulation 33 of the Listing Regulations

To
The Board of Directors of Aurobindo Pharma Limited

We have reviewed the accompanying statement of unaudited standalone financial results ("the Statement") of Aurobindo Pharma Limited ("the Company") for the quarter ended 30 June 2018, attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('Listing Regulations'). Attention is drawn to the fact that the figures for the 3 months ended 31 March 2018 as reported in these standalone financial results are the balancing figures between audited figures in respect of the full previous financial year and the published year to date figures up to the third quarter of the previous financial year. The figures up to the end of the third quarter of previous financial year had only been reviewed and not subjected to audit.

This Statement is the responsibility of the Company's Management and has been approved by the Board of Directors on 09 August 2018. Our responsibility is to issue a report on the Statement based on our review.

We conducted our review in accordance with the Standard on Review Engagement ('SRE') 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" specified under Section 143(10) of the Companies Act, 2013. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of Company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Corresponding figures for the quarter ended 30 June 2017 included in the Statement were reviewed by the predecessor auditor who expressed an unmodified opinion dated 09 August 2017.




Limited Review Report on quarterly unaudited standalone financial results of Aurobindo Pharma Limited pursuant to Regulation 33 of the Listing Regulations *(continued)*

Based on our review conducted as stated above, nothing has come to our attention that causes us to believe that the accompanying Statement prepared in accordance with applicable accounting standards i.e. Ind AS prescribed under Section 133 of the Companies Act, 2013 and other recognised accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For B S R & Associates LLP

Chartered Accountants

Firm Registration Number: 110231W/ W-100024



Amit Kumar Agarwal

Partner

Membership Number: 214198

Place: Hyderabad

Date: 09 August 2018

AUROBINDO PHARMA LIMITED
(CIN - L24239TG1986PLC015190)

Regd. Office: Plot No.2, Maitriviham, Ameerpet, Hyderabad - 500 038, India
Tel: +91 040 23736370 ; Fax: +91 40 23747340 ; Email: info@aurobindo.com

(Rs. In lakhs)


STATEMENT OF CONSOLIDATED UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30.06.2018

Particulars	Quarter ended		Year ended	
	30.06.2018	31.03.2018	30.06.2017	31.03.2018
	Unaudited	Audited	Unaudited	Audited
1 Revenue from operations				
(a) Net sales/ income from operations (refer note 4)	418,156	398,863	362,107	1,623,287
(b) Other operating income	6,871	6,046	5,768	26,697
Total revenue from operations	425,027	404,909	367,875	1,649,984
2 Other income	4,373	4,383	2,209	10,198
Total income (1+2)	429,400	409,292	370,084	1,660,182
3 Expenses				
(a) Cost of materials consumed	165,678	142,779	137,833	562,937
(b) Purchases of stock-in-trade	43,513	46,673	34,041	160,588
(c) Changes in inventories of finished goods, stock-in-trade and work-in-progress	(18,466)	(22,505)	(22,091)	(48,251)
(d) Employee benefits expense	59,613	58,127	49,017	213,084
(e) Finance costs	2,954	2,472	1,687	7,771
(f) Foreign exchange loss (net) (refer note 8)	6,816	1,592	766	1,676
(g) Depreciation and amortisation expense	15,453	15,663	13,118	55,797
(h) Other expenses	96,767	99,432	84,915	382,774
Total expenses	372,328	344,233	299,286	1,336,376
4 Profit before tax (1+2-3)	57,072	65,059	70,798	323,806
5 Share of profit of joint ventures, net of tax	41	56	134	314
6 Profit before tax (4+5)	57,113	65,115	70,932	324,120
7 Tax expense	11,554	12,239	19,099	81,828
8 Net profit for the period (6-7)	45,559	52,876	51,833	242,292
9 Share of (loss)/profit attributable to non-controlling interest	(7)	25	(18)	(26)
10 Net profit after taxes attributable to owners of the Parent Company (8-9)	45,566	52,851	51,851	242,318
11 Other Comprehensive income				
i) items that will not be reclassified subsequently to profit or loss (net of tax)	(63)	196	(158)	(237)
ii) items that will be reclassified subsequently to profit or loss	3,526	10,184	3,330	15,191
Total other comprehensive income	3,463	10,380	3,172	14,954
12 Total Comprehensive income for the period (10+11)	49,029	63,231	55,023	257,272
13 Paid-up equity share capital (face value Re. 1 per share)	5,859	5,859	5,859	5,859
14 Other equity				1,162,183
15 Earnings per equity share of Re. 1 each (not annualised)				
(a) Basic (in Rs.)	7.78	9.02	8.85	41.36
(b) Diluted (in Rs.)	7.78	9.02	8.85	41.36

NOTES:

- The financial results of the Company have been prepared in accordance with the Indian Accounting Standards (Ind AS) prescribed under Section 133 of the Companies Act, 2013, read with the relevant rules issued thereunder.
- The above consolidated financial results have been prepared in accordance with principles and procedures as set out in the Ind AS 110 on "Consolidated financial statements" and Ind AS 28 on "Investments in Associates and Joint Ventures" notified under Section 133 of Companies Act, 2013 and Companies (Indian Accounting Standards) Rules, 2015, as amended.
- The above consolidated financial results as reviewed by the audit committee have been approved by Board of Directors at its meeting held on 09 August 2018.
- Post implementation of Goods and Services Tax ('GST') with effect from 01 July 2017, revenues from operations is disclosed net of GST. Revenue from operations for the quarter ended 30 June 2018 and 31 March 2018 are reported net of GST. Revenue from operations for the quarter ended 30 June 2017 includes excise duty which is now subsumed in GST. The year ended 31 March 2018 includes excise duty upto 30 June 2017.
- Effective 01 April 2018, the Company has adopted Ind AS 115 "Revenue from Contracts with Customers". The adoption of the standard did not have material impact on the financial results of the Group.
- During the quarter, i) Mer Medicamentos, Lda, Portugal, Aurovitas, Unipessoal LDA, Portugal and Aurobindo Pharma (Portugal) Unipessoal Limitada., Portugal were merged with Generis Farmaceutica S.A., w.e.f. 01 April 2018. ii) Aurobindo Pharma USA LLC was revived w.e.f. 06 June 2018, which was dissolved w.e.f. 31 March 2018.
- The Company operates in only one segment viz., 'Pharmaceutical Products'.
- Foreign exchange loss includes exchange difference arising from foreign currency borrowings to the extent that they are regarded as an adjustment to finance cost as per para 6(e) of Ind AS 23 on "Borrowing costs".
- The figures for the quarter ended 31 March 2018 are the balancing figures between audited figures in respect of the full financial year upto 31 March 2018 and the unaudited published year to date figures upto 31 December 2017, which were subjected to the limited review only by the statutory auditors.
- Previous period figures have been regrouped/ rearranged wherever considered necessary to conform to the current period presentation.

Place: Hyderabad
Date : 09 August 2018



By Order of the Board

N. Govindarajan
Managing Director



FOR IDENTIFICATION ONLY

B S R & Associates LLP

Chartered Accountants

Salarpuria Knowledge City
Orwell, 6th Floor, Unit-3
Sy. No. 83/1, Plot No. 2, Raidurg
Hyderabad-500081, India

Telephone : +91 40 7182 2000
Fax : +91 40 7182 2399

Limited Review Report on unaudited quarterly consolidated financial results of Aurobindo Pharma Limited pursuant to the Regulation 33 of the Listing Regulations

To
The Board of Directors of Aurobindo Pharma Limited

We have reviewed the accompanying statement of unaudited consolidated financial results ("the Statement") of Aurobindo Pharma Limited ('the Company'), its subsidiaries (collectively referred to as 'the Group') and its joint ventures as listed in Annexure I, for the quarter ended 30 June 2018 attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('Listing Regulations'). Attention is drawn to the fact that the figures for the 3 months ended 31 March 2018 as reported in these financial results are the balancing figures between audited figures in respect of the full previous financial year and the published year to date figures up to the third quarter of the previous financial year. The figures up to the end of the third quarter of previous financial year had only been reviewed and not subjected to audit.

This Statement is the responsibility of the Company's Management and has been approved by the Board of Directors on 09 August 2018. Our responsibility is to issue a report on the Statement based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, '*Review of Interim Financial Information Performed by the Independent Auditor of the Entity*' specified under Section 143(10) of the Companies Act, 2013. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of Company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

We did not review the unaudited financial information of 18 subsidiaries included in the Statement, whose unaudited financial information reflect total revenues (including other income) of Rs. 260,526 lakhs for the quarter ended 30 June 2018. This unaudited financial information has been reviewed by other auditors whose reports have been furnished to us, and our opinion on the Statement, to the extent they have been derived from such unaudited financial information is based solely on the report of such other auditors. Our conclusion is not modified in respect of such matter.



Limited Review report on unaudited quarterly consolidated financial results of Aurobindo Pharma Limited pursuant to the Regulation 33 of the Listing Regulations (continued)

Certain of these subsidiaries are located outside India whose financial results and other financial information have been prepared in accordance with accounting principles generally accepted in their respective countries and which have been reviewed by other auditors under generally accepted auditing standards applicable in their respective countries. The Company's Management has converted the financial statements of such subsidiaries located outside India from accounting principles generally accepted in their respective countries to accounting principles generally accepted in India. We have reviewed these conversion adjustments made by the Company's Management. Our conclusion in so far as it relates to the balances and affairs of such subsidiaries located outside India is based on the report of other auditors and the conversion adjustments prepared by the Management of the Company and reviewed by us.

Corresponding figures for the quarter ended 30 June 2017 included in the Statement were reviewed by the predecessor auditor who expressed an unmodified opinion dated 09 August 2017.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement prepared in accordance with applicable accounting standards i.e. Ind AS prescribed under Section 133 of the Companies Act, 2013 and other recognised accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations including the manner in which it is to be disclosed, or that it contains any material misstatement.

For **B S R & Associates LLP**

Chartered Accountants

Firm Registration Number: 116231 W/ W-100024



Amit Kumar Agarwal

Partner

Membership Number: 214198

Place: Hyderabad

Date: 09 August 2018

Limited Review report (continued)**Annexure I**

List of subsidiaries and joint ventures

S.No.	Component Name	Country	Relationship
1	APL Research Centre Limited	India	Subsidiary
2	APL Healthcare Limited	India	Subsidiary
3	Auronext Pharma Private Limited	India	Subsidiary
4	Silicon Life Sciences Private Limited	India	Subsidiary
5	Auro Peptides Limited	India	Subsidiary
6	APL Pharma Thai Limited	Thailand	Subsidiary
7	All Pharma (Shanghai) Trading Company Limited	China	Subsidiary
8	Aurobindo Pharma USA Inc.	USA	Subsidiary
9	Natrol LLC	USA	Subsidiary
10	Aurolife Pharma LLC	USA	Subsidiary
11	Auro Health LLC	USA	Subsidiary
12	Auromedics Pharma LLC	USA	Subsidiary
13	Aurobindo Pharma USA LLC (dissolved w.e.f. 31 March 2018, revived w.e.f. 06 June 2018)	USA	Subsidiary
14	Auro AR LLC (w.e.f. 02 May 2017)	USA	Subsidiary
15	Auro Vaccines LLC	USA	Subsidiary
16	Auro Logistics LLC (w.e.f. 28 April 2017)	USA	Subsidiary
17	Aurobindo Pharma Produtos Farmaceuticos Limitada	Brazil	Subsidiary
18	Helix Healthcare B.V.	The Netherlands	Subsidiary
19	Aurogen South Africa (Pty) Ltd	South Africa	Subsidiary
20	Aurobindo Pharma (Pty) Limited	South Africa	Subsidiary
21	Novagen Pharma (Pty) Limited	South Africa	Joint venture
22	Auro Pharma Inc.	Canada	Subsidiary
23	Aurovida Farmaceutica SA DE CV	Mexico	Subsidiary
24	Auro Healthcare (Nigeria) Limited	Nigeria	Subsidiary
25	Aurobindo Pharma Japan K.K.	Japan	Subsidiary
26	Aurobindo Pharma Colombia S.A.S	Colombia	Subsidiary
27	Agile Pharma B.V.	The Netherlands	Subsidiary
28	Arrow Generiques SAS	France	Subsidiary
29	1980 Puren Pharma GmbH (formerly Actavis Management GmbH)	Germany	Subsidiary
30	Puren Pharma GmbH & Co., KG (formerly Actavis Deutschland GmbH & Co., KG)	Germany	Subsidiary
31	Aurovitas Spain SA (formerly Actavis Spain S.A)	Spain	Subsidiary
32	Aurobindo Pharma B.V. (formerly known as Actavis B.V.)	The Netherlands	Subsidiary
33	Aurex B.V. (formerly known as Pharmacin B.V.)	The Netherlands	Subsidiary
34	Aurobindo Pharma GmbH	Germany	Subsidiary
35	Aurobindo Pharma (Portugal) Unipessoal Limitada (Merged with Generis Farmaceutica S.A w.e.f 01 April 2018)	Portugal	Subsidiary

A

Limited Review report (continued)**Annexure I (continued)**

List of subsidiaries and joint ventures

S.No.	Component Name	Country	Relationship
36	Laboratorios Aurobindo S.L.	Spain	Subsidiary
37	Aurobindo Pharma (Italia) S.r.l	Italy	Subsidiary
38	Aurobindo Pharma (Romania) S.r.l.	Romania	Subsidiary
39	Aurovitas, Unipessoal LDA (Merged with Generis Farmaceutica S.A w.e.f 01 April 2018)	Portugal	Subsidiary
40	Pharmacin B.V. (formerly known as Aurex B.V.)	The Netherlands	Subsidiary
41	Aurobindo Pharma (Malta) Limited	Malta	Subsidiary
42	APL Swift Services (Malta) Limited	Malta	Subsidiary
43	Milpharm Limited	United Kingdom	Subsidiary
44	Aurovitas Pharma Polska	Poland	Subsidiary
45	Generis Farmaceutica S.A (w.e.f. 01 May 2017)	Portugal	Subsidiary
46	Mer Medicamentos, Lda. (w.e.f. 01 May 2017, merged with Generis Farmaceutica S.A. w.e.f 01 April 2018)	Portugal	Subsidiary
47	Generis Phar, Unipessoal Lda. (w.ef. 01 May 2017)	Portugal	Subsidiary
48	Aurobindo Pharma Saudi Arabia Limited Company (w.e.f. 08 May 2017)	Saudi Arabia	Subsidiary
49	Aurobindo Pharma Industria Farmaceutica Ltda	Brazil	Subsidiary
50	Hyacinths Pharma Private Limited	India	Subsidiary
51	Raidurgam Developers Limited (Formerly Aurobindo Antibiotics Ltd)	India	Joint Venture
52	AuroZymes Limited	India	Subsidiary
53	Curepro Parenterals Limited	India	Subsidiary
54	Eugia Pharma Specialities Limited	India	Joint venture
55	Tergene Biotech Private Limited	India	Joint venture
56	Auro Pharma India Private Limited (w.e.f. 20 December 2017)	India	Subsidiary
57	Aurovitas Pharma Ceska republika s.r.o (w.e.f. 23 December 2017)	Czech Republic	Subsidiary
58	Aurovitas Pharma (Taizhou) Ltd (w.e.f. 29 January 2018)	China	Subsidiary
59	Acrotech Biopharma LLC (w.e.f. 05 January 2018)	USA	Subsidiary